PROBLEM TO BE SOLVED: To obtain an oral preparation useful for chronic cardiac insufficiency, excellent in shelf stability of a forskolin derivative salt, by using both the forskolin derivative and a specific alkali metal compound. SOLUTION: This oral preparation comprises a forskolin derivative salt and a halogenated alkali metal as medicinal components. A compound of the formula [R1 is H; R4 is vinyl, ethyl or cyclopropyl; one of R2 and R3 is CO (CH2 )m NR5 R6 (R5 and R6 are each H, an alkyl or R5 and R6 are bonded to form an alkylene; (m) is 1-5) and the other is H or CO(CH2 )n X [X is NR7 R8 (R7 and R8 are each H, an alkyl, etc.); (n) is 1-5]] is preferable as the forskolin salt. Sodium chloride or potassium chloride is preferable as the halogenated alkali metal. The amount of the halogenated alkali metal is preferably 0.01-26 pts.wt. based on 1 pt.wt. of the forskolin derivative.
展开▼
机译:解决的问题:通过同时使用毛喉素衍生物和特定的碱金属化合物,获得可用于慢性心脏功能不全,毛喉素衍生物盐的贮存稳定性优异的口服制剂。溶液:该口服制剂包含福斯高林衍生物盐和卤代碱金属作为药用成分。式[R 1]的化合物为H。 R 4为乙烯基,乙基或环丙基; R 2和R 3之一为CO(CH 2)m NR 5 R 6(R 5和R 6各自为H,烷基或R 5和R 6 >键合形成亚烷基;(m)为1-5),另一个为H或CO(CH 2)n X [X为NR 7 R 8(R 7和R 8为每个H,烷基等); (n)为1〜5]]作为毛喉素盐是优选的。优选氯化钠或氯化钾作为卤化碱金属。卤化碱金属的量优选为0.01-26pts.wt。根据1磅重量的福司柯林衍生物。
展开▼